FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199028049> ?p ?o ?g. }

• W3199028049 endingPage "41" @default.
• W3199028049 startingPage "28" @default.
• W3199028049 abstract "Benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS) is diagnosed in up to 80% of men during their lifetime. Several novel ultra-minimally invasive surgical treatments (uMISTs) for BPH/benign prostatic obstruction (BPO) have become available over the past 5 yr. To evaluate the perioperative and functional outcomes of recently introduced uMISTs for BPH/BPO, including Urolift, Rezūm, temporary implantable nitinol device, prostatic artery embolization (PAE), and intraprostatic injection. A systematic literature search was conducted in December 2020 using Medline (via PubMed), Embase (via Ovid), Scopus, and Web of Science (registered on PROSPERO as CRD42021225014). The search strategy used PICO criteria and article selection was conducted in accordance with the PRISMA guidelines. The risk of bias and the quality of the articles included were assessed. A dedicated data extraction form was used to collect the data of interest. Pooled and cumulative analyses were performed to compare perioperative and functional outcomes between study groups. A random-effects model using the DerSimonian and Laird method was used to evaluate heterogeneity. Stata version 15.0 software was used for all statistical analyses. The initial electronic search identified 3978 papers, of which 48 ultimately met the inclusion criteria and were included in the analysis. Pooled analysis revealed a uMIST benefit in terms of International Prostate Symptom Score (IPSS; −9.81 points, 95% confidence interval [CI] −11.37 to −8.25 at 1 mo; −13.13 points, 95% CI −14.98 to −11.64 at 12 mo), maximum flow rate (from +3.66 ml/s, 95% CI 2.8–4.5 to +4.14 ml/s, 95% CI 0.72–7.56 at 12 mo), and postvoid residual volume (−10.10 ml, 95% CI −27.90 to 7.71 at 12 mo). No negative impact was observed on scores for the International Index of Erectile Function-5, Male Sexual Health Questionnaire-Ejaculatory Dysfunction bother and function scales (overall postintervention change in pooled median score of 1.88, 95% CI 1.34–2.42 at the start of follow-up; and 1.04, 95% CI 0.28–1.8 after 1 yr), or the IPSS-Quality of Life questionnaire. Novel uMISTs can yield fast and effective relief of LUTS without affecting patient quality of life. Only Rezūm, UroLift, and PAE had a minimal impact on patients’ sexual function with respect to baseline, especially regarding preservation of ejaculation. We reviewed outcomes for recently introduced ultra-minimally invasive surgical treatments for patients with lower urinary tract symptoms caused by benign prostate enlargement or obstruction. The evidence suggests that these novel techniques are beneficial in terms of controlling symptoms while preserving sexual function. Novel ultra-minimally invasive treatments can yield fast and effective relief of lower urinary tract symptoms without affecting a patient’s quality of life." @default.
• W3199028049 created "2021-09-27" @default.
• W3199028049 creator A5001969970 @default.
• W3199028049 creator A5015869739 @default.
• W3199028049 creator A5024284158 @default.
• W3199028049 creator A5025441151 @default.
• W3199028049 creator A5029580242 @default.
• W3199028049 creator A5035053038 @default.
• W3199028049 creator A5037607528 @default.
• W3199028049 creator A5038137057 @default.
• W3199028049 creator A5038625374 @default.
• W3199028049 creator A5039276554 @default.
• W3199028049 creator A5040694356 @default.
• W3199028049 creator A5044003979 @default.
• W3199028049 creator A5045112039 @default.
• W3199028049 creator A5046168299 @default.
• W3199028049 creator A5048032405 @default.
• W3199028049 creator A5048861007 @default.
• W3199028049 creator A5050834286 @default.
• W3199028049 creator A5051194589 @default.
• W3199028049 creator A5054546622 @default.
• W3199028049 creator A5058121703 @default.
• W3199028049 creator A5062586182 @default.
• W3199028049 creator A5067209639 @default.
• W3199028049 creator A5073837396 @default.
• W3199028049 creator A5077469192 @default.
• W3199028049 creator A5078353258 @default.
• W3199028049 creator A5081058129 @default.
• W3199028049 creator A5082997583 @default.
• W3199028049 creator A5083745890 @default.
• W3199028049 creator A5084824445 @default.
• W3199028049 date "2021-11-01" @default.
• W3199028049 modified "2023-10-14" @default.
• W3199028049 title "New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes" @default.
• W3199028049 cites W1004710628 @default.
• W3199028049 cites W11499841 @default.
• W3199028049 cites W1480729244 @default.
• W3199028049 cites W1497769826 @default.
• W3199028049 cites W1531324422 @default.
• W3199028049 cites W1537972189 @default.
• W3199028049 cites W1601296207 @default.
• W3199028049 cites W1616423488 @default.
• W3199028049 cites W1796387324 @default.
• W3199028049 cites W1890241494 @default.
• W3199028049 cites W1978630268 @default.
• W3199028049 cites W1985493799 @default.
• W3199028049 cites W1986215651 @default.
• W3199028049 cites W2006882610 @default.
• W3199028049 cites W2007872832 @default.
• W3199028049 cites W2013816708 @default.
• W3199028049 cites W2030470179 @default.
• W3199028049 cites W2037473701 @default.
• W3199028049 cites W2038693293 @default.
• W3199028049 cites W2050026651 @default.
• W3199028049 cites W2086561958 @default.
• W3199028049 cites W2095572883 @default.
• W3199028049 cites W2096998881 @default.
• W3199028049 cites W2098923148 @default.
• W3199028049 cites W2104882900 @default.
• W3199028049 cites W2106677608 @default.
• W3199028049 cites W2109818195 @default.
• W3199028049 cites W2119187895 @default.
• W3199028049 cites W2144766519 @default.
• W3199028049 cites W2152788789 @default.
• W3199028049 cites W2161230641 @default.
• W3199028049 cites W2165010366 @default.
• W3199028049 cites W2339404802 @default.
• W3199028049 cites W2344653515 @default.
• W3199028049 cites W2346970875 @default.
• W3199028049 cites W2465075917 @default.
• W3199028049 cites W2531269403 @default.
• W3199028049 cites W2551370105 @default.
• W3199028049 cites W2552791027 @default.
• W3199028049 cites W2561329298 @default.
• W3199028049 cites W2581547855 @default.
• W3199028049 cites W2588681363 @default.
• W3199028049 cites W2622257203 @default.
• W3199028049 cites W2777464921 @default.
• W3199028049 cites W2781307532 @default.
• W3199028049 cites W2789960417 @default.
• W3199028049 cites W2790910465 @default.
• W3199028049 cites W2807720204 @default.
• W3199028049 cites W2809631697 @default.
• W3199028049 cites W2811134567 @default.
• W3199028049 cites W2884891702 @default.
• W3199028049 cites W2900551948 @default.
• W3199028049 cites W2904247792 @default.
• W3199028049 cites W2910806689 @default.
• W3199028049 cites W2938456744 @default.
• W3199028049 cites W2941146473 @default.
• W3199028049 cites W2945293219 @default.
• W3199028049 cites W2954405062 @default.
• W3199028049 cites W2970684805 @default.
• W3199028049 cites W2978230325 @default.
• W3199028049 cites W2978795816 @default.
• W3199028049 cites W2981626026 @default.
• W3199028049 cites W2990750799 @default.
• W3199028049 cites W2991189808 @default.

• next